The CBY1 (Chibby homolog 1) antibody is a research tool targeting the CBY1 protein, a conserved component of the β-catenin degradation complex. CBY1. initially identified in Drosophila, functions as an antagonist of the Wnt/β-catenin signaling pathway by binding to β-catenin and promoting its nuclear export and degradation. This interaction regulates cell proliferation, differentiation, and embryonic development. CBY1 also localizes to the base of primary cilia, implicating it in ciliogenesis and Hedgehog signaling. Dysregulation of CBY1 is linked to ciliopathies and cancers, particularly prostate and colorectal cancers, where altered expression may influence tumor progression.
The CBY1 antibody is widely used in studies exploring Wnt signaling dynamics, ciliary biology, and cancer mechanisms. Applications include Western blotting, immunofluorescence, and immunohistochemistry to detect CBY1 expression, subcellular localization, and interaction partners. Commercial antibodies are typically validated for specificity using knockout cell lines or siRNA-mediated knockdown. Researchers employ CBY1 antibodies to investigate its role in tissue development, stem cell regulation, and disease models, particularly in contexts of β-catenin hyperactivity or ciliary dysfunction. Recent studies also highlight CBY1's involvement in cellular stress responses, expanding its relevance in metabolic and neurodegenerative disorders.